Laronde
Amulya Kaza is an accomplished Associate Scientist at Sail Biomedicines with expertise in developing circular RNA-based monoclonal antibodies for serious infectious diseases. Kaza previously served as a Senior Research Associate, demonstrating the application of the circular RNA platform across novel therapeutic modalities, including precision CRISPR medicines, and as a Research Associate 2 establishing therapeutic use cases in the monoclonal antibody market. Prior experience includes advancing gene editing programs at Vertex Pharmaceuticals and developing a patient-specific drug screening platform at Duke University Pratt School of Engineering. Amulya Kaza holds a Master’s degree in Biomedical Engineering from Duke University and a Bachelor’s degree in Mechanical Engineering from Delhi Technological University.